Thyroid eye disease

Seminars in Ophthalmology

Volumn 14, Issue 2, 1999, Pages 52-61

  Scott, Ingrid U ^a   Siatkowski, R Michael ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIURETIC AGENT; IMMUNOSUPPRESSIVE AGENT; LUBRICATING AGENT; METHOTREXATE;

CAROTID CAVERNOUS FISTULA; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; DIFFERENTIAL DIAGNOSIS; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOS; EXTRAOCULAR MUSCLE; EYE SURGERY; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOGENESIS; MYOSITIS; ORBIT METASTASIS; ORBIT PSEUDOTUMOR; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; TOPICAL DRUG ADMINISTRATION;

EID: 0032983957     PISSN: 08820538     EISSN: None     Source Type: Journal    
DOI: 10.3109/08820539909056064     Document Type: Review

References (139)

1. Parry CH. Enlargement of thyroid gland in connection with enlargement or palpitation of the heart. In: Collections From Unpublished Writings of Late Caleb Hillier Parry (vol 2). London: Underwoods, 1825;111.
2. Graves RJ. Newly observed affection of the thyroid gland in females. Lond Med Surg J. 1985;7:516.
3. Von Basedow CA. Exophthalmos durch hypertrophie des cellgewebes in der augenhoele. Wochenschr Ges Heilk. 1840; 6:197-220.
4. Cooper WW. On protrusion of the eyes in connection with anemia, palpitation and goitre. Lancet. 1849;1:551.
5. Dobyns BM. Present concepts of pathologic physiology of exophthalmos. J Clin Endocrinol Metab. 1950;10:1202.
6. Askanasy M. Pathologische-Anatomische beitraege zur kenntnis des morbus basedowii, insbesonders ueber die dabei auftretende muskelerkrankung. Dtsch Arch Klin Med. 1898; 61:118.
7. Sattler H. Ueber den sogenannten landstroemischen muskel und seine bedeutung fur den exophthalmus bei morbus basedowii. Ber Versamml Ophthalmol Ges Heidelberg. 1911; 37:181.
8. Mulvany JH. Exophthalmos of hyperthyroidism (part I). Am J Ophthalmol. 1944;27:589-612.
9. Aran FA. De la nature et du traitement de l'affection connue sous le nom de goitre exophtalmique, cachexia exoptalmique, maladie de basedow. Bull Acad Med. 1860-1861;26:122.
10. Marine D. Studies on pathological physiology of exophthalmos of Graves' disease. Ann Intern Med. 1938;12:443.
11. Bernard C. Lecons sur la Physiologie et la Pathologie due Systeme Nerveux (vol 2). Paris: JB Balliere et Fils, 1858:499.
12. Loeb J, Friedman H. Exophthalmos produced by injections of acid extract of anterior pituitary gland of cattle. Proc Soc Exp Biol Med. 1932;29:648.
13. Smelser GK. A comparative study of experimental and clinical exophthalmos. Am J Ophthalmol. 1937;20:1189-1203.
14. Werner SC. Classification of eye changes of Graves' disease. J Clin Endocrinol. 1969;29:982-984.
15. Werner SC. Modification of the classification of the eye changes of Graves' disease: recommendations of the Ad Hoc Committee of the American Thyroid Association. J Clin Endocrinol Metab. 1977;44:203-204.
16. Bartley GB. Evolution of classification systems for Graves' ophthalmopathy. Ophthal Plast Reconstr Surg. 1995; 11:229-237.
17. Donaldson SS, Bagshaw MA, Kriss JP. Supervoltage orbital radiotherapy for Graves' ophthalmopathy. J Clin Endocrinol Metab. 1973;37:276-285.
18. Van Dyk HJL. Orbital Graves' disease: A modification of the NO SPECS classification. Ophthalmology. 1981;88: 479-483.
19. Kahaly G, Schrezenmeir J, Krause U, et al. Cyclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: A controlled, randomized and prospective study. Eur J Clin Invest. 1986;16:415-422.
20. Bartalena L, Marcocci G, Bogazzi R, et al. A new ophthalmopathy index for quantitation of eye changes of Graves' disease. Acta Endocrinol (Copenh). 1989;121:190.
21. German C. Clever is not enough: NO SPECS if form in search of function. Thyroid. 1991;1:353-355.
22. Frueh BR. Why the NO SPECS classification of Graves' eye disease should be abandoned, with suggestions for the characterization of this disease. Thyroid. 1992;2:85-88.
23. Mourits M, Prummel MF, Wiersinga WM, et al. Measuring eye movements in Graves' ophthalmopathy. Ophthalmology. 1994;101:1341-1346.
24. Pinchera A, Wiersinga W, Glinoer D, et al. Classification of eye changes of Graves' disease. Thyroid. 1992;2:235.
25. Drescher EP, Benedict WL. Asymmetric exophthalmos. Arch Ophthalmol. 1950;44:109-128.
26. Grove AS Jr. Evaluation of exophthalmos. N Engl J Med. 1975;292:1005-1013.
27. Dallow RL. Evaluation of unilateral exophthalmos with ultrasonography: Analysis of 258 consecutive cases. Laryngoscope. 1975;85:1905-1919.
28. Char DH, Norman D. The use of computed tomography and ultrasonography in the evaluation of orbital masses. Surv Ophthalmol. 1982;27:49-63.
29. O'Brien CS, Leinfelder PJ. Unilateral exophthalmos: Etiologic and diagnostic studies in 82 consecutive cases. Am J Ophthalmol. 1935;18:123-132.
30. Rundle FF, Wilson CW. Asymmetry of exophthalmos in orbital tumor and Graves' disease. Lancet. 1945;1:51.
31. Saltzman SL, Mellicker MC. Unilateral exophthalmos as a forerunner of thyrotoxicosis. Am J Ophthalmol. 1951;34: 372-374.
32. Moss HM. Expanding lesions of the orbit: A clinical study of 230 consecutive cases. Am J Ophthalmol. 1962;54:761-770.
33. Newman NM. Neuro-Ophthalmology. A Practical Text. Norwalk, CT: Appleton & Lange; 1992;276-287.
34. Bartels EC. Thyroid function in patients with progressive exophthalmos: Study of 117 cases requiring orbital decompression. In: Pitt-Rivers R, ed: Advances in Thyroid Research. New York: Pergamon; 1961:163.
35. Hamilton RD, Mayberry WE, McConahey WM, et al. Ophthalmopathy of Graves' disease: A comparison between patients treated surgically and patients treated with radioiodide. Mayo Clin Proc. 1967;42:812-818.
36. Gorman CA. Temporal relationship between onset of Graves' ophthalmopathy and diagnosis of thyrotoxicosis. Mayo Clin Proc. 1983;58:515-519.
37. Gorman CA. The presentation and management of endocrine ophthalmopathy. J Clin Endocrinol Metab. 1978;7:67-96.
38. Aranow H Jr, Day RM. Management of thyrotoxicosis in patients with ophthalmopathy: Antithyroid regimen determined primarily by ocular manifestations. J Clin Endocrinol Metab. 1965;25:1.
39. Jones DI, Munro DS, Wilson GM. Observations on the course of exophthalmos after I-131 therapy. Proc R Soc Med. 1969;62:15-18.
40. Werner SC, Coelho B, Quimby EH. Ten year results of I-131 therapy of hyperthyroidism. Bull NY Acad Med. 1957; 33:783.
41. Hamilton HE, Schultz RO, De Gowinel EL. The endocrine eye lesion in hyperthyroidism. Arch Intern Med. 1960; 105:675.
42. Metz HS, Woolf PD, Patton ML. Endocrine ophthalmopathy in adolescence. J Pediatr Ophthalmol Strabismus. 1982;19:58-60.
43. Young LA. Dysthyroid ophthalmopathy in children. J Pediatr Ophthalmol Strabismus. 1979;16:105-107.
44. Nordyke RA, Gilbert FL Jr, Harada ASM. Graves' disease. Influence of age on clinical findings. Arch Intern Med. 1988;148:626-631.
45. Uretsky SH, Kennerdell JS, Guta JP. Graves' ophthalmopathy in childhood and adolescence. Arch Ophthalmol. 1980;98:1963-1964.
46. Bram I. Exophthalmic goiter in children: Comments based upon 128 cases in patients of 12 and under. Arch Pediatr. 1937;54:419.
47. Stout AU, Borchert M. Etiology of eyelid retraction in children: A retrospective study. J Pediatr Ophthalmol Strabismus. 1993;30:96-99.
48. 131I: A review of 500 cases. Br Med J. 1959;1:63.
49. Jacobson DH, German CA. Endocrine ophthalmopathy: Current ideas concerning etiology, pathogenesis and treatment. Endocr Rev. 1984;5:200-220.
50. Jones IR. The pathogenesis and treatment of Graves' ophthalmopathy. Postgrad Med J. 1987;63:731-733.
51. Bartley GB, Fatourechi V, Kadrmas EF, et al. The incidence of Graves' ophthalmopathy in Olmstead County, Minnesota. Am J Ophthalmol. 1995;120:511-517.
52. Siatkowski RM, Capo H, Byrne SF, et al. Clinical and echographic findings in idiopathic orbital myositis. Am J Ophthalmol. 1994;118:343-350.
53. Goldberg L, Tao A, Romano P. Severe exophthalmos secondary to orbital myopathy not due to graves' disease. Br J Ophthalmol. 1982;66:392-395.
54. Char DH, Unsold R. Ocular and Orbital Pathology: Clinical Aspects. In: Newton TH, Hasso AN, Dillon WP, eds. Modern Neuroradiology (vol 3): Computed Tomography of the Head and Neck. Kentfield, IA: Clavadel Press; 1988.
55. Ashton N, Morgan G. Discrete carcinomatous metastases in the extraocular muscles. Br J Ophthlamol. 1974;58:112-117.
56. Barnes C. Orbital myositis - a case report. Aust NZ J Ophthalmol. 1990;18:251-255.
57. Slavin ML, Glaser JS. Idiopathic orbital myositis: Report of six cases. Arch Ophthalmol. 1982;100:1261-1265.
58. Casteels I, De Bleecker C, Demaerel P, et al. Orbital myositis following an upper respiratory tract infection: Contribution of high resolution CT and MRI. J Belge Radiologie. 1991;74:45-47.
59. Wolter JR, Hoy JE, Schmidt DM. Chronic orbital myositis. Its diagnostic difficulties and pathology. Am J Ophthalmol. 1966;62:292-298.
60. Bullen CL, Younge BR. Chronic orbital myositis. Arch Ophthalmol. 1982;100:1749-1751.
61. Trokel SL, Jakobiec FA. Correlation of CT scanning and pathologic features of ophthalmic Graves' disease. Ophthalmology. 1981;88:553-564.
62. Lenderink T, Jager MJ, Bruijn JA, et al. Immunohistology of eye muscle in idiopathic orbital inflammatory disease (pseudotumor), Graves' ophthalmopathy and healthy controls. Graefe's Arch Clin Exp Ophthalmol. 1993;231:99-103.
63. Jellinek EH. The orbital pseudotumor syndrome and its differentiation from endocrine exophthalmos. Brain. 1969; 92:35-58.
64. Dunnington JG, Berke RN. Exophthalmos due to chronic orbital myositis. Arch Ophthalmol. 1943;30:446-465.
65. Bessant DA, Lee JP. Management of strabismus due to orbital myositis. Eye. 1995;9:558-563.
66. Hornblass A, Jakobiec FA, Feifler DM, et al. Orbital lymphoid tumours located predominantly within extraocular muscles. Ophthalmology. 1987;94:688-697.
67. Sergott RC, Glaser JS. Graves' ophthalmopathy. A clinical and immunologic review. Surv Ophthalmol. 1981;26:1-21.
68. Weinstein GS, Dresner SC, Slamovits TL, et al. Acute and subacute orbital myositis. Am J Ophthalmol. 1983;96:209-217.
69. Sekhar GC, Mandal AK, Byas P. Nonspecific orbital inflammatory diseases. Doc Ophthalmologica. 1993;84:155-170.
70. Dunne JW, Edis RH. Optic nerve involvement in Graves' ophthalmopathy: A case report and review. Aust NZ J Med. 1985;15:258-261.
71. Enzmann D, Marshall WH Jr, Rosenthal AR, et al. Computed tomography in Graves' ophthalmopathy. Radiology. 1976;118:615-620.
72. Hankey GJ, Silbert PL, Edis RH, et al. Orbital myositis: A study of six cases. Aust NZ J Med. 1987;17:585-591.
73. Byrne SF, Green RL. Ultrasound of the Eye and Orbit. St. Louis, MO: CV Mosby; 1992:353-392.
74. Trokel SL, Hilal SK. Recognition and differential diagnosis of enlarged extraocular muscles in computed tomography. Am J Ophthalmol. 1979;87:503-512.
75. Char DH. Thyroid Eye Disease, 3rd ed. Boston, MA: Butterworth-Heinemann; 1997:63-111.
76. Dua HS, Smith FW, Singh AK, et al. Diagnosis of orbital myositis by nuclear magnetic resonance imaging. Br J Ophthalmol. 1987;71:54-57.
77. Lockie P. Acute orbital myositis: a case report. Aust NZ J Ophthalmol. 1985;13:287-291.
78. Bach MC, Knowland M, Schuyler WB. Acute orbital myositis mimicking orbital cellulitis. Ann Internal Med. 1988;109:243-245.
79. Divine RD, Anderson RL. Small cell carcinoma masquerading as orbital myositis. Ophthalmic Surg. 1982;13:433-487.
80. Patrinely JR, Osborn AG, Anderson RL, et al. Computed tomographic features of nonthyroid extraocular muscle enlargement. Ophthalmology. 1989;96:1038-1047.
81. Dresner SC, Rothfus WE, Slamovits TL, et al. Computed tomography of orbital myositis. AJR. 1984;143:671-674.
82. Mauriello JA Jr, Flanagan JC. Management of orbital inflammatory disease. A protocol. Surv Ophthalmol. 1984; 29:104-116.
83. Peyster RG, Hoover ED. Computerized Tomography in Orbital Disease and Neuro-ophthalmology. Chicago, IL: Year Book Medical Publishers; 1984:23-116.
84. Fernbach SK, Naidich TP. CT diagnosis of orbital inflammation in children. Neuroradiology. 1981;22:7-13.
85. Nugent RA, Rootman J, Robertson WD, et al. Acute orbital pseudotumors: Classification and CT features. AJNR. 1981;2:431-436.
86. Enzmann DR, Donaldson SS, Kriss JP. Appearance of Graves' disease on orbital computed tomography. J Comput Assist Tomogr. 1979;3:815-819.
87. Rothfus WE, Curtin HD. Extraocular muscle enlargement: A CT review. Radiology. 1984;151:677-681.
88. Ross WH. Myositic pseudotumor of the orbit. Can J Ophthalmol. 1983;18:199-201.
89. Unsold R, Ostertag CH, Newton TH. Zur Differentialdiagnose endokriner Orbitopathien und entzundlicher Pseudotumoren der Orbita. Computertomographie-Befunde. Klin Monatsbl Augenheilkd. 1980;177:31-47.
90. Jakobiec FA. Non-infectious orbital inflammation. In: Spencer WH ed. Ophthalmic Pathology. An Atlas and Textbook, 4th ed. vol 4. Philadelphia, PA: WB Saunders; 1996:2810-2859.
91. Rush JA, Older JJ. Graves' ophthalmopathy and the thyrotropin-releasing hormone (TRH) test. J Clin Neurol Ophthalmol. 1981;1:219-224.
92. Solomon DH, Chopra IJ, Chopra U, et al. Identification of subgroups of euthyroid Graves' ophthalmopathy. N Engl J Med. 1977;296:181-186.
93. Solomon DH, Chopra IJ. Ophthalmopathy and thyroid disorders. N Engl J Med. 1977;296:1003.
94. Sridama V, DeGroot LJ. Treatment of Graves' disease and the course of ophthalmopathy. Am J Med. 1989;87:70-73.
95. Hart IR, McKenzie JM. Comparison of the effects of thyrotropin and the long-acting thyroid stimulator on guinea pig adipose tissue. Endocrinology. 1971;88:26-30.
96. Gill DL, Marshall NJ, Elkins RP. Binding of thyrotropin to receptors in fat tissue. Mol Cell Endocrinol. 1978;10:89-102.
97. Doniach D. The pathogenesis of endocrine exophthalmos: A short review. Proc R Soc Med. 1977;70:695-698.
98. McKenzie JM, McCullagh EP. Observations against a causal relationship between the long-acting thyroid stimulator and ophthalmopathy in Graves' disease. J Clin Endocrinol 1968;28:1177-1182.
99. Teng CS, Smith BR, Clayton B, et al. Thyroid-stimulating immunoglobulin in ophthalmic Graves' disease. Clin Endocrinol (Oxf). 1977;6:207-211.
100. Feldt-Rasmussen U, Kemp A, Bech K, et al. Serum thyroglobulin, its autoantibody and thyroid stimulating antibodies in the endocrine exophthalmos. Acta Endocrinol (Copenh). 1981;96;192.
101. Rapoport B, Greenspan FS, Filetti S, et al. Clinical experience with a human thyroid cell bioassay for thyroid-stimulating immunoglobulin. J Clin Endocrinol Metab. 1984;58: 332-338.
102. Atta HR, McCreath G, McKillop JH, et al. Ophthalmopathy in early thyrotoxicosis - relationship to thyroid receptor antibodies and effects of treatment. Scott Med J. 1990;35:41-44.
103. Yamamoto K, Saito K, Takai T, et al. Diagnosis of exophthalmos using orbital ultrasonography and treatment of malignant exophthalmos with steroid therapy, orbital radiation therapy, and plasmapheresis. Prog Clin Biol Res. 1983;116: 189-205.
104. Brohee D, Delespesse G, Debisscop MJ, et al. Circulating immune complexes in various thyroid diseases. Clin Exp Immunol. 1979;36:379.
105. Solem JH, Segaard E, Ytteborg J. The course of endocrine ophthalmopathy during antithyroid therapy in a prospective study. Acta Med Scand. 1979;205:111-114.
106. McLachlan SM, Bahn RS, Gorman CA. In patients with Graves' ophthalmopathy, severity is positively correlated with levels of TSH receptor antibody. Endocrinology. 1987;120:28 (suppl).
107. Hiromatsu Y, Wang PW, Wosu L, et al. Mechanisms of immune damage in Graves' ophthalmopathy. Horm Res. 1987;26:198-207.
108. Wang PW, Hiromatsu Y, Laryea E, et al. Immunologically mediated cytotoxicity against human eye muscles in Graves' ophthalmopathy. J Clin Endocrinol Metab. 1986; 63:316-322.
109. Kodama K, Sikorska H, Bandy-Dafoe P, et al. Demonstration of a circulating autoantibody against a soluble eye-muscle antigen in Graves' ophthalmopathy. Lancet. 1982; 2:1353-1356.
110. Faryna M, Nauman J, Gardas A. Measurement of autoantibodies against human eye muscle plasma membranes in Graves' ophthalmopathy. Br Med J. 1985;290:191-192.
111. Kendall-Taylor P. The pathogenesis of Graves' ophthalmopathy. Clin Endocrinol Metab. 1985;14:331-349.
112. Ahmann A, Baker JR, Weetman AP, et al. Antibodies to porcine eye muscle in patients with Graves' ophthalmopathy: Identification of serum immunoglobulins directed against unique determinants by immunoblotting and enzyme-linked immunoabsorbent assay. J Clin Endocrinol Metab. 1987;64:454-460.
113. Kendall-Taylor P, Jones D, Atkinson S. The specificity of autoantibodies in Graves' disease. Acta Endocrinol (Copenh). 1987;281:330-333 (suppl).
114. Mahieu R, Winand R. Demonstration of delayed hypersensitivity in retrobulbar and thyroid tissues in human exophthalmos. J Clin Endocrinol Metab. 1972;34:1090.
115. Blau HM, Kaplan I, Tao T-W, et al. Thyroglobulin independent, cell-mediated cytotoxicity of human eye muscle cells in tissue culture by lymphocytes of a patient with Graves' ophthalmopathy. Life Sci. 1983;32:45-53.
116. Duke-Elder S. System of Ophthalmology, vol 13. St Louis, MO: CV Mosby; 1974.
117. Yamamoto K, Itoh K, Yoshida S, et al. A quantitative analysis of orbital soft tissue in Graves' disease based on B-mode ultrasonography. Endocrinol Jpn. 1979;26:255-261.
118. Amino N, Yuasa T, Yabu Y, et al. Exophthalmos in autoimmune thyroid disease. J Clin Endocrinol Metab. 1980; 51:1232-1234.
119. Grove AS. Evaluation of exophthalmos. N Engl J Med. 1975;292:1005.
120. Wiersinga WM, Smit T, van der Gaag R, et al. Clinical presentation of graves' ophthalmopathy. Ophthalmic Res. 1989;21:73-82.
121. Skalka HW. The use of ultrasonography in the diagnosis of endocrine orbitopathy. Neuro-ophthalmol. 1980;1:109-116.
122. Forrester JV, Sutherland GR, McDougall IR. Dysthyroid ophthalmopathy: Orbital evaluation with B-scan ultrasonography. J Clin Endocrinol Metab. 1977;45:221-224.
123. Hodes BL, Stern G. Contact B-scan echographic diagnosis of ophthalmic Graves' disease. J Clin Ultrasound. 1975; 3:255-261.
124. Trobe JD, Glaser JS, Laflamme P. Dysthyroid optic neuropathy. Clinical profile and rationale for management. Arch Ophthalmol. 1978;96:1199-1209.
125. Gasser P, Flammer J. Optic neuropathy of Graves' disease. A report of perimetric follow up. Ophthalmologica. 1986;192:22-27.
126. Winand R, Mahieu R. Prevention of malignant exophthalmos after treatment of thyrotoxicosis. Lancet. 1973;1: 1196.
127. Burrow GN, Mitchell MS, Howard RO, et al. Immunosuppressive therapy for the eye changes of Graves' disease. J Clin Endocrinol 1970;31:307-311.
128. Wall JR, Strakosch CR, Fang SL, et al. Thyroid binding antibodies and other immunological abnormalities in patients with Graves' ophthalmopathy: Effect of treatment with cyclophosphamide. Clin Endocrinol (Oxf). 1979;10:79-91.
129. Bigos ST, Nisula BC, Daniels GH, et al. Cyclophosphamide in the management of advanced Graves' ophthalmopathy. A preliminary report. Ann Intern Med. 1979;90:921-923.
130. Dyer JA. The oculorotatory muscles in Graves' disease. Trans Am Ophthalmol Soc. 1976;74:425-456.
131. Wall JR, Henderson J, Strakosch CR, Joyner PM. Graves' ophthalmopathy. Can Med Assoc J. 1981;124:855-862.
132. Peters O, Schreuer R, Vanhaelst L. Endocrine ophthalmopathy and asymptomatic atrophic thyroiditis. An unusual association. Acta Clin Belg. 1985;40:17-21.
133. Perros P, Weightman DR, Crombie AL, et al. Azathioprine in the treatment of thyroid-associated ophthalmopathy. Act Endocrinol (Copenh). 1990;122:8-12.
134. Prummel MF, Mourits MP, Berghout A, et al. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med. 1989;321:1353-1359.
135. Kahaly G, Schrezenmeir J, Kruse U, et al. Cyclosporine and prednisone in treatment of Graves' ophthalmopathy: A controlled, randomized, prospective study. Eur J Clin Invest. 1986;16:415-422.
136. Utech C, Wulle KG, Bieler EU, et al. Treatment of severe Graves' ophthalmopathy with cyclosporin A. Acta Endocrinol (Copenh). 1985;110:493-498.
137. Weissel M, Zielinski CC, Hauff W, et al. Combined therapy with cyclosporin A and cortisone in Basedow endocrine orbitopathy: Successful use in compressive optic neuropathy. Act Med Austriaca. 1993;20(1-2):9-13.
138. Hudson HL, Feldon SE. Late overcorrection of hypotropia in Graves ophthalmopathy. Ophthalmology. 1992; 99:356-360.
139. Sprunger DT, Helveston EM. Progressive overcorrection after inferior rectus recession. J Pediatr Ophthalmol Strabismus 1993;30:145-148.